BRIEF published on 05/13/2025 at 07:05, 8 months 18 days ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 8 months 18 days ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 8 months 29 days ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
BRIEF published on 04/29/2025 at 21:05, 9 months 1 day ago Innate Pharma Presents Promising Preclinical Data for IPH4502 at AACR 2025 Preclinical Data Innate Pharma IPH4502 Nectin-4 Antibody Drug Conjugate
PRESS RELEASE published on 04/29/2025 at 21:00, 9 months 1 day ago Inside Information / Other news releases Innate Pharma presents preclinical data for IPH4502, a Nectin-4 targeting ADC, showing superior anti-tumor efficacy in multiple cancer models at AACR 2025 Annual Meeting Preclinical Data Innate Pharma IPH4502 AACR 2025 Nectin-4 ADC
BRIEF published on 04/24/2025 at 07:40, 9 months 6 days ago Innate Pharma Secures €15M Sanofi Investment Capital Increase Innate Pharma Sanofi Investment BCMA ANKET Biotech Partnership
PRESS RELEASE published on 04/24/2025 at 07:35, 9 months 6 days ago Inside Information / Other news releases Innate Pharma announces €15M investment by Sanofi to strengthen collaboration and support pipeline execution. Closing of the capital increase expected on April 25, 2025 Investment Collaboration Sanofi Innate Pharma Pipeline Execution
BRIEF published on 04/23/2025 at 07:05, 9 months 7 days ago Innate Pharma Takes Back Rights and Sanofi Considers Investment Strategic Investment Sanofi Innate Pharma Acute Myeloid Leukemia CD123
PRESS RELEASE published on 04/23/2025 at 07:00, 9 months 7 days ago Inside Information / Other news releases Innate Pharma regains rights on CD123 targeting ANKET® as Sanofi plans strategic investment. SAR'579 (IPH6101) ongoing study shows promise in AML patients Strategic Investment Sanofi Innate Pharma CD123 Targeting SAR'579
BRIEF published on 04/16/2025 at 07:05, 9 months 14 days ago Innate Pharma General Meeting Announced for May 22, 2025 Shareholders Biotechnology General Meeting Innate Pharma Marseille
Published on 01/31/2026 at 03:15, 1 day 3 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 4 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 7 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 14 hours 38 minutes ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 18 hours 7 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 3 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 8 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 10 hours ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 1 day 12 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 2 days 12 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 12 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 12 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
